Myanmar
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 53 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 26 (16–38) 49 (29–71)
Mortality (HIV+TB only) 4.3 (3.3–5.3) 8 (6.3–9.9)
Prevalence  (includes HIV+TB) 250 (190–320) 473 (364–595)
Incidence  (includes HIV+TB) 200 (180–220) 373 (340–413)
Incidence (HIV+TB only) 17 (16–18) 33 (30–34)
Case detection, all forms (%) 68 (61–74)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 5 (3.1–6.8) 27 (15–39)
MDR-TB cases among notified pulmonary
TB cases
5 700 (3 500–7 700) 3 300 (1 800–4 800)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 42 595   4 854
Pulmonary, clinically diagnosed 70 519    
Extrapulmonary 16 887    
       
Total new and relapse 134 855    
Previously treated, excluding relapses 7 307    
Total cases notified 142 162    
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 527 (13%) 8 551 (70%) 14 246
Laboratory-confirmed RR-/MDR-TB cases     1 984
Patients started on MDR-TB treatment     667
TB/HIV 2013 Number (%)
TB patients with known HIV status 16 882 (12)
HIV-positive TB patients 5 413 (32)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 826 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 3 987 (74)
HIV-positive people screened for TB 45 337  
HIV-positive people provided with IPT 468  
Treatment success rate (%)
New cases registered in 2012 89
Previously treated cases registered in 2012 70
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 71
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 24
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 36
% Funded domestically 15%
% Funded internationally 49%
% Unfunded 35%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-27 Data: www.who.int/tb/data